22 Leading Neoantigen Targeted Therapies Companies Shaping Precision Oncology: Competitive Analysis & Market Leaders to Watch Through 2030
Explore the most influential companies driving the Neoantigen Targeted Therapies market and learn how they are setting new standards for precision immunotherapy and personalized cancer care. Dive deeper with full market insights by accessing the Neoantigen Targeted Therapies Market by Therapy Modality, Treatment Approach, Route of Administration, Age Group, Target Disease Indication, End-User - Global Forecast to 2030 report.
Spotlight: Leading Neoantigen Targeted Therapies Companies (2025–2030)
The global neoantigen targeted therapies market is rapidly evolving, propelled by breakthroughs in precision medicine, genomic profiling, and immunotherapy innovation. As highlighted in recent forecasts, the sector is set to more than double in value, driven by dynamic leaders committed to advancing patient-specific cancer solutions. Below, we profile the top 22 companies innovating in this high-growth arena.
1. Achilles Therapeutics Limited
Known for its focus on developing personalized T cell therapies targeting clonal neoantigens, Achilles Therapeutics leverages advanced bioinformatics and multi-omic approaches to enable precise targeting of tumor-specific mutations. Their technology is poised to significantly enhance outcomes in solid tumor immunotherapy.
2. Agenus Inc.
Agenus is a trailblazer in immuno-oncology, specializing in the creation of neoantigen-based vaccines and checkpoint antibodies. The company’s innovative platforms bridge personalized vaccine development and combination approaches, bolstering immune response in diverse cancer types.
3. AstraZeneca plc
AstraZeneca brings global scale and robust R&D to the neoantigen therapies space, integrating precision immunotherapy with existing oncology assets. Strategic partnerships amplify their leadership in genomic profiling and individualized treatment regimens for complex cancers.
4. BioNTech SE
A pioneer in mRNA therapeutics, BioNTech employs cutting-edge platforms to create patient-specific neoantigen vaccines and cell therapies. Their deep expertise in genomics and translational research has led to several clinical-stage candidates targeting advanced malignancies.
5. Bristol‑Myers Squibb Company
As a major player in cancer immunotherapy, Bristol-Myers Squibb combines neoantigen innovation with checkpoint inhibitors and established treatment regimens. Their research focuses on broadening indications and achieving durable patient responses through personalized approaches.
6. CureVac N.V.
CureVac harnesses proprietary mRNA technology to engineer vaccines targeting unique tumor mutations. Their neoantigen pipeline emphasizes broad population access and scalable manufacturing—key factors in meeting global demand for personalized cancer immunotherapies.
7. EpiVax, Inc.
EpiVax leverages advanced computational immunology for rapid neoantigen discovery and vaccine development. Their platforms are designed to accelerate clinical translation and support customized therapeutic strategies for oncologists and biopharma partners.
8. F. Hoffmann-La Roche AG
Roche’s commitment to oncology innovation encompasses neoantigen-targeted therapeutics, with a focus on integrated solutions spanning genomics, diagnostics, and novel immunotherapies. Their global network enables rapid clinical development and commercialization.
9. Genentech, Inc.
As a Roche subsidiary, Genentech leads in the integration of artificial intelligence and genomic analytics for neoantigen identification. Their collaborative model connects research, clinical trials, and manufacturing, facilitating rapid adoption of breakthrough therapies.
10. Genocea Biosciences, Inc.
Genocea specializes in T cell-targeted oncology vaccines, using proprietary antigen discovery platforms. By focusing on patient-tailored antigen profiles, Genocea aims to unlock highly specific and effective treatment responses for difficult-to-treat cancers.
11. GlaxoSmithKline plc
GSK’s expansive oncology pipeline includes bespoke neoantigen therapies, addressing both prevalent and rare malignancies. Their investment in bioinformatics and immune modulation supports a diverse range of therapeutic candidates and combination strategies.
12. Gritstone bio, Inc.
Gritstone bio is renowned for its expertise in AI-enabled sequencing and neoantigen prediction, creating next-generation vaccines and cell therapies that precisely target tumor mutations. Their partnerships with leading research institutes reinforce clinical advancements.
13. Immatics N.V.
Immatics bridges advanced target discovery with engineered T cell therapies, focusing on intracellular tumor antigens. Their collaborations with both pharma giants and academic centers are accelerating personalized immunotherapy options for solid tumors.
14. Immunomic Therapeutics, Inc.
Immunomic leverages proprietary UNITE® technology to optimize neoantigen presentation, enhancing immune response against cancer cells. Their translational research supports rapid movement from pre-clinical validation to patient-centric clinical programs.
15. Medigene AG
Medigene utilizes T cell receptor (TCR) technology to target neoantigens associated with hard-to-treat cancers. Their platforms offer robust specificity and potency, positioning Medigene as a partner of choice for precision immunotherapy co-development.
16. Merck & Co., Inc.
Merck amplifies its role in immuno-oncology by integrating neoantigen platforms with blockbuster therapies, such as checkpoint inhibitors. Their commitment to large-scale clinical trials and global access supports wide-reaching market impact and continued innovation.
17. Moderna, Inc.
Moderna has established itself as a leader in mRNA-based neoantigen vaccines, scaling rapid vaccine design and developmental processes. Their investments in AI, digital manufacturing, and global regulatory navigation power broad access to their pipeline.
18. Neon Therapeutics, Inc.
Neon Therapeutics, now part of BioNTech, brought proprietary approaches to neoantigen target identification and personalized vaccine formulation. Their legacy continues to influence BioNTech’s expanding precision oncology portfolio.
19. Nykode Therapeutics
Nykode specializes in modular vaccine technology, enabling rapid creation of personalized neoantigen vaccines. Their approach streamlines development timelines and increases the agility of clinical deployments in diverse tumor types.
20. Pfizer Inc.
As an industry heavyweight, Pfizer’s foray into neoantigen therapies centers on leveraging global clinical trial capabilities and partnerships. Their integrated pipeline supports both monotherapy and combination approaches to personalized immuno-oncology.
21. Precision Biologics
Precision Biologics is at the forefront of antibody-based therapies targeting cancer-specific neoantigens. With an emphasis on monoclonal antibody development and collaborative clinical research, the company enhances specificity and efficacy in precision oncology.
22. Valo Therapeutics Ltd
Valo Therapeutics merges viral vector platforms with neoantigen payloads, pioneering innovative delivery systems that improve immunogenicity and enable flexible personalization for cancer immunotherapy patients across multiple indications.
Conclusion: Accelerate Your Neoantigen Strategy with In-Depth Market Intelligence
The companies spotlighted above are setting the pace for transformative change in the neoantigen targeted therapies market, forging strategic collaborations and redefining standards in precision oncology. To unlock the full spectrum of competitive insights, technology trends, and growth forecasts shaping this dynamic sector through 2030, access the authoritative Neoantigen Targeted Therapies Market by Therapy Modality, Treatment Approach, Route of Administration, Age Group, Target Disease Indication, End-User - Global Forecast to 2030 report today.
Discover the top 22 leading neoantigen targeted therapies companies reshaping precision oncology. Competitive analysis, market leaders, and future trends through 2030.